Olema Pharmaceuticals (OLMA) closed at $8.04 on November 11, 2026, up 10.6% from the previous close, on volume of 1,734,146 shares (30-day average 1,248,303).
Data as of November 11, 2026.
11-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 10, 2026. See the 10 largest for 30, 60 and 90 days
TipRanks (Wed, 11-Nov 5:40 AM ET)
Olema Pharmaceuticals GAAP EPS of -$0.73 misses by $0.10
Seeking Alpha News (Tue, 10-Nov 7:14 AM ET)
Olema Oncology Reports Third Quarter 2026 Financial and Operating Results
Globe Newswire (Tue, 10-Nov 7:00 AM ET)
Globe Newswire (Wed, 4-Nov 4:01 PM ET)
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Tue, 3-Nov 4:30 PM ET)
Olema Oncology to Participate in Upcoming Investor Conferences
Globe Newswire (Mon, 2-Nov 4:30 PM ET)
Olema Oncology Appoints Jason O'Byrne as Chief Financial Officer
Globe Newswire (Thu, 13-Aug 7:00 AM ET)
Market Chameleon (Fri, 22-May 3:50 AM ET)
Olema Oncology to Highlight Its Advancing Pipeline at Three Major Investor Conferences
Market Chameleon (Wed, 20-May 4:43 AM ET)
Market Chameleon (Wed, 19-Nov 5:30 AM ET)
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
Olema Pharmaceuticals trades on the NASDAQ stock market under the symbol OLMA.
As of November 11, 2026, OLMA stock price climbed to $8.04 with 1,734,146 million shares trading.
OLMA has a beta of 0.81, meaning it tends to be less sensitive to market movements. OLMA has a correlation of 0.01 to the broad based SPY ETF.
OLMA has a market cap of $704.35 million. This is considered a Small Cap stock.
Last quarter Olema Pharmaceuticals reported $0 in Revenue and -$.73 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$.10.
In the last 3 years, OLMA traded as high as $36.26 and as low as $2.86.
The top ETF exchange traded funds that OLMA belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWN.
OLMA has underperformed the market in the last year with a return of -7.6%, while the SPY ETF gained +12.6%. In the last 3 month period, OLMA fell short of the market, returning -32.7%, while SPY returned -1.5%. However, in the most recent 2 weeks OLMA has outperformed the stock market by returning +14.2%, while SPY returned -1.3%.
OLMA support price is $6.91 and resistance is $7.63 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OLMA shares will trade within this expected range on the day.
